Related Experiment Video
Updated: May 28, 2026
A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
Published on: February 7, 2025
Dynamics of glial fibrillary acidic protein during traumatic brain injury in children
1Department of Anesthesia and Intensive Care, University Children's Hospital, Brno, Czech Republic. jzurek@fnbrno.cz
Insights
Serum glial fibrillary acidic protein (GFAP) levels can help assess brain damage severity and predict outcomes in children with traumatic brain injury (TBI). Higher GFAP levels indicate a worse prognosis after TBI.
Area of Science:
- Neuroscience
- Biomarkers
- Trauma Research
Background:
- Glial fibrillary acidic protein (GFAP) is a brain-specific intermediate filament protein.
- GFAP is released into the bloodstream following traumatic brain injury (TBI).
Purpose of the Study:
- To investigate the utility of serum GFAP levels in assessing TBI severity and predicting outcomes in children.
- To correlate GFAP levels with injury severity and patient outcomes.
Main Methods:
- Prospective study of 59 children with TBI confirmed by CT scan.
- Daily serum GFAP measurements via ELISA for 6 days post-admission.
- Outcome assessment using the Glasgow Outcome Scale (GOS) at 6 months.
Main Results:
- Significantly higher GFAP levels at admission in non-survivors (7.47 ng/mL) versus survivors (0.12 ng/mL).
- Elevated GFAP levels correlated with poor outcomes at 6 months post-injury (p<0.001).
- High diagnostic accuracy for GFAP with AUCs of 0.833 (day 0) and 0.884 (day 2).
Conclusions:
- Serum GFAP levels may enhance clinical assessment of primary brain damage.
- GFAP determination shows potential for predicting outcomes in severe pediatric TBI.
- GFAP serves as a valuable biomarker for TBI severity and prognosis.
Backgrounds:
Glial fibrillary acidic protein (GFAP) is a monomeric intermediate filament protein found in the astroglial cytoskeleton and is not found outside the central nervous system. It is a brain-specific protein that is released after traumatic brain injury (TBI).
Methods:
This prospective study enrolled 59 children who had TBI, as verified by computed tomography. Daily GFAP measurement began at admission (<12 hours after trauma) and continued for 6 days. Blood samples were analyzed for GFAP by enzyme-linked immunosorbent assay. Outcome was assessed using the Glasgow Outcome Scale (GOS) at 6 months after injury.
Results:
The median serum levels of GFAP at admission were 7.47 ng/mL in patients who died, compared with 0.12 ng/mL in patients who survived (p=0.002). GFAP levels were significantly higher in patients who had a poor outcome 6 months after injury than in those who were alive or had good outcome (p<0.001). The area under the receiver operating characteristic curve for GFAP was 0.833 for day 0 and 0.884 for day 2.
Conclusions:
These results suggest that determination of serum levels of GFAP may add to the clinical assessment of the primary damage and prediction of outcome after severe TBI.
